The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot that can protect babies from respiratory syncytial virus, adding an additional ...

Kennedy selected a new team of medical professionals and scientists who are looking at vaccines are highly qualified.

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

However, ACIP recommendations are tremendously influential in how vaccines are used in the US, with implications for insurance coverage and state policies. Advisers endorse Merck RSV antibody ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

ACIP's first meeting: Inside the unusual, RFK-appointed panel that's deciding on childhood vaccines Merck's shot is the second RSV monoclonal antibody of its kind on the market.